HLA-DRB1 and myeloid sarcoma: Individuals positive for EBNA-1 fragment 385–420, positive for HLA-DRB1*15 and negative for HLA-A*02 had a 16-fold increased risk of MS (OR = 16.03, 95% CI 9.42–27.20) [148].